Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for the Treatment of Ocular Diseases
- Tuesday, June 1, 2021, 7:11
- PR Newswire
- Add a comment
HOUSTON and SAN DIEGO, June 1, 2021 /PRNewswire/ — Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-mediated gene therapies for the treatment of ocular diseases, and Hopstem Biotechnology, the leading human induced pluripotent stem cell (hiPSC)…
About the Author
admin has written 20655 stories on this site.